Navigation Links
Watson Reaches Settlement with Mallinckrodt Over Exalgo(R)
Date:1/26/2012

istorical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release. It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business. These factors include, among others, the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's quarterly report on form 10-Q for the quarter ended September 30, 2011 and Watson's annual report on Form 10-K for the year ended December 31, 2010. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

Exalgo® is a registered trademark of Mallinckrodt LLC. CONTACTS:Investors: 

Patty Eisenhaur  

(862) 261-8141 

  Media: 

Charlie Mayr 

(862) 261-8030(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO )


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
3. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
4. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
5. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
6. Watson and Barr Settle Lawsuit Over Oxytrol(R)
7. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook
8. Watson Completes Acquisition of Eden Biodesign
9. Watson to Present at Credit Suisse Healthcare Conference
10. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
11. Watson Files FDA Application for Generic Rozerem(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)...   Mast Therapeutics, Inc. (NYSE MKT: ... Santosh Vetticaden, Chief Medical Officer and Senior Vice ... reasons, in mid-September.  Edwin L. Parsley , ... which Mast acquired earlier this year, will assume ... Chief Medical Officer.  Dr. Parsley previously was with ...
(Date:8/29/2014)... Research and Markets has announced ... Market & Pipeline Insight 2014" report to their ... prevent and eradicate the prevalence of cancer have achieved ... to low specificity, safety and large number of side ... better solution. It has been discovered that peptides can ...
(Date:8/29/2014)...  United Therapeutics Corporation (NASDAQ: UTHR ) ... District of New Jersey has ... Sandoz, Inc. regarding United Therapeutics, Remodulin ® product.  In ... U.S. Patent No. 6,765,117 is both valid and enforceable ... generic product until the expiration of that patent in ...
Breaking Medicine Technology:Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2District Court Decision Received In Remodulin Patent Case 2
... off daily GERD medication at 1 year ... after transoral incisionless fundoplication surgery, REDMOND, Wash., ... natural orifice surgery products and procedures, announces,outstanding results ... patients,in the phase 2 multi-center study of the ...
... Dong-A PharmTech Co., Ltd.,announced today that its ... patient, phase 2 proof of concept clinical study ... phosphodiesterase type 5 inhibitor, for,portal hypertension, an unmet ... investigate the safety and efficacy of udenafil in ...
Cached Medicine Technology:EndoGastric Solutions(TM) Announces Results of EsophyX(TM) Multi-Center GERD Study 2EndoGastric Solutions(TM) Announces Results of EsophyX(TM) Multi-Center GERD Study 3EndoGastric Solutions(TM) Announces Results of EsophyX(TM) Multi-Center GERD Study 4Dong-A PharmTech Co., Ltd. Announces Portal Hypertension Clinical Trial With Udenafil 2Dong-A PharmTech Co., Ltd. Announces Portal Hypertension Clinical Trial With Udenafil 3
(Date:8/29/2014)... Healthpointe is pleased to provide ... students via Clinical Rotations. Physical Therapy ... Healthpointe providers and specialists throughout their daily clinical ... experience and learn professional preparation. , ... into several patient care techniques and expand their ...
(Date:8/29/2014)... 2014 Pursuing its deepest desires to ... unveil a stunning new design that promises to redefine ... highly notable surrogacy platform has witnessed a 42 percent ... visitors a month, the FindSurrogateMother.com community is formed by ... common goal — the precious gift of life. , ...
(Date:8/29/2014)... based on administering antidepressants for acute and chronic ... are needed to determine whether these drugs should ... basis., Dr. Ian Gilron, a professor and director ... Anesthesiology, and his team of seven researchers reviewed ... antidepressants for pain relief post-surgery would work more ...
(Date:8/29/2014)... Grove Village, IL (PRWEB) August 29, 2014 ... innovator in hearing wellness solutions, is on its way ... 15-17 at the San Diego Convention Center to exhibit ... those who work in high-noise industrial environments. Etymotic’s safety ... the hottest wearable technology devices at the show. ...
(Date:8/29/2014)... Elk Grove Village, IL (PRWEB) August 29, 2014 ... welcomed Kathleen Baty, “The Safety Chick” who profiled ... including ETY•Kids® Safe-Listening Earphones from Etymotic Research. This ... school supply list, and Etymotic, an innovator of ... for young ears. Their ETY•Kids Safe-Listening Earphones, offered ...
Breaking Medicine News(10 mins):Health News:Healthpointe is Now Offering Clinical Rotations for Chapman University Physical Therapy Students 2Health News:FindSurrogateMother.com Set to Unveil Stunning New Design as Member Sign-ups Increase by 42% since January 2Health News:FindSurrogateMother.com Set to Unveil Stunning New Design as Member Sign-ups Increase by 42% since January 3Health News:Antidepressants show potential for postoperative pain 2Health News:Etymotic’s Safe Listening Earphones and Earplugs Headed For The 2014 NSC Safety Expo 2Health News:The Today Show Features ETY•Kids® Safe-Listening Earphones by Etymotic 2
... Today at 9:00am ET , , Covers Europe, ... , , Includes Licensing Option and ... Calif. and STAINES, England, June 22 NeurogesX, Inc. (Nasdaq: ... Tokyo based Astellas Pharma Inc. announced today that the companies have entered ...
... ... company , ... Colo. (PRWEB) June 22, 2009 -- Silver Creek Systems®, the pioneer and ... that their DataLens™ System was selected by McKesson Medical-Surgical to automate the processes that ...
... "Anesthesia & Me"(C) Checklist to Help Patients Organize ... , LifelinetoModernMedicine.com Provides Patients with Physician-Certified Tools ... 22 Every year, 46 million Americans face ... help educate and inform prospective patients and the ...
... self-help technique called guided imagery has been steadily gaining ... insurance companies, as new research demonstrates its efficacy for ... June 22 A new self-help audio recording designed ... or other viral and bacterial illnesses was released this ...
... June 22 /PRNewswire-Asia/ -- The Healthcare & Science,business ... a Memorandum of,Understanding (MOU) with the Science & ... organization under the National,Applied Research Laboratories in Taiwan, ... Taiwan,s Science & Technology (S&T) development. , ...
... , ... resource in the compounding pharmacy industry had just been released by Esco. The videos ... ... announces the release of its new series of safety and education videos for the ...
Cached Medicine News:Health News:NeurogesX and Astellas Enter Commercialization Agreement for Qutenza(TM) 2Health News:NeurogesX and Astellas Enter Commercialization Agreement for Qutenza(TM) 3Health News:NeurogesX and Astellas Enter Commercialization Agreement for Qutenza(TM) 4Health News:NeurogesX and Astellas Enter Commercialization Agreement for Qutenza(TM) 5Health News:NeurogesX and Astellas Enter Commercialization Agreement for Qutenza(TM) 6Health News:McKesson Medical-Surgical Selects DataLens System to Automate Product Data Mastering 2Health News:American Society of Anesthesiologists Launches Web Site Focused on Educating and Empowering the Public about Anesthesiology 2Health News:American Society of Anesthesiologists Launches Web Site Focused on Educating and Empowering the Public about Anesthesiology 3Health News:Cancer Patients Use New Guided Imagery CD to Help Boost Healthy Immune Functioning 2Health News:Cancer Patients Use New Guided Imagery CD to Help Boost Healthy Immune Functioning 3Health News:Taiwan's Science & Technology Policy Research and Information Center (STPI) and Thomson Reuters Sign MOU of Collaboration to Support Science & Technology Development 2Health News:Taiwan's Science & Technology Policy Research and Information Center (STPI) and Thomson Reuters Sign MOU of Collaboration to Support Science & Technology Development 3Health News:New Compounding Pharmacy Videos Provide Product Information, Teach Safety 2Health News:New Compounding Pharmacy Videos Provide Product Information, Teach Safety 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: